http://www.zibb.com/all/theme/cq/Dendreon+Corporation Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Fri, 20 Nov 2009 21:37:14 GMTFri, 20 Nov 2009 21:37:14 GMT608831http://www.zibb.com/all/theme/cq/Dendreon+Corporation http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://seattle.bizjournals.com/seattle/stories/2009/11/16/daily47.html?ana=from_rss&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%253A+vertical_32+%2528Biotechnology+Industry+News%2529said the U.S. Food and Drug Administration said it will make a regulatory decision on the biotech’s Provenge prostate cancer drug by May 1, 2010. The Seattle biotech (NASDAQ: DNDN) said the FDA provided written acknowledgment of Dendreon’s application for Provenge.http://seattle.bizjournals.com/seattle/stories/2009/11/16/daily47.html?ana=from_rss&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%253A+vertical_32+%2528Biotechnology+Industry+News%2529Dendreon CorporationFri, 20 Nov 2009 21:37:14 GMThttp://abcnews.go.com/Business/wireStory?id=9137116Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1. The drug is aimed at treating prostate cancer.http://abcnews.go.com/Business/wireStory?id=9137116Dendreon CorporationFri, 20 Nov 2009 15:54:46 GMThttp://www.newsvine.com/_news/2009/11/20/3525464-dendreons-provenge-gets-fda-review-dateBiotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1.http://www.newsvine.com/_news/2009/11/20/3525464-dendreons-provenge-gets-fda-review-dateDendreon CorporationFri, 20 Nov 2009 15:54:01 GMThttp://www.xconomy.com/seattle/2009/11/20/dendreon-fda-deadline-set-for-may-1/Seattle-based Dendreon (NASDAQ: ]), the developer of what it hopes will be the first FDA-approved treatment to actively stimulate the immune system againsthttp://www.xconomy.com/seattle/2009/11/20/dendreon-fda-deadline-set-for-may-1/Dendreon CorporationFri, 20 Nov 2009 14:21:55 GMThttp://www.biospace.com/news_story.aspx?StoryID=163582&full=1SEATTLE, Nov 20, 2009 /PRNewswire-FirstCall via COMTEX/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE(R) (sipuleucel-T) is ahttp://www.biospace.com/news_story.aspx?StoryID=163582&full=1Dendreon CorporationFri, 20 Nov 2009 12:00:00 GMThttp://www.zibb.com/article/5684397/xtremepicks+com+www+Xtremepicks+Com+Xtremepicks+Alerts+November+DNDN+POZN+VCLK+and+NUANXtremepicks.com Alerts include Dendreon Corporation (Nasdaq: DNDN), POZEN Inc. (NASDAQ: POZN), ValueClick, Inc. (Nasdaq: VCLK) and Nuance Communications (NASDAQ: NUAN) Dendreon Corporation (Nasdaq: DNDN) trading at $27.94 per share on trading volume of 1.43M shares. In a press release out onhttp://www.zibb.com/article/5684397/xtremepicks+com+www+Xtremepicks+Com+Xtremepicks+Alerts+November+DNDN+POZN+VCLK+and+NUANDendreon CorporationFri, 20 Nov 2009 11:08:25 GMThttp://www.moneyweek.com/investment-advice/share-tips-two-promising-biotech-stocks-to-watch-94610.aspxLouis Basenese picks two small-cap biotech stocks that he thinks could be set to soar.http://www.moneyweek.com/investment-advice/share-tips-two-promising-biotech-stocks-to-watch-94610.aspxDendreon CorporationThu, 12 Nov 2009 08:33:00 GMThttp://finance.yahoo.com/news/Big-Pharma-Again-Taking-Shot-ibd-295236225.html?x=0The news lately has been all about H1N1. Serious as the swine flu pandemic is, the vaccine is pretty ordinary from a scientific point 15f view.http://finance.yahoo.com/news/Big-Pharma-Again-Taking-Shot-ibd-295236225.html?x=0Dendreon CorporationTue, 03 Nov 2009 23:26:43 GMThttp://www.foxbusiness.com/story/markets/industries/health-care/dendreon-files-early-provenge/Dendreon (DNDN) announced on Monday that its prostate cancer drug Provenge has gone through the Food and Drug Administration application ahead of its 2010 predicted schedule.http://www.foxbusiness.com/story/markets/industries/health-care/dendreon-files-early-provenge/Dendreon CorporationMon, 02 Nov 2009 22:48:23 GMThttp://www.thestreet.com/_yahoo/story/10620223/1/dendreon-resubmits-provenge-to-fda-biobuzz.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NAApproval decision for prostate cancer vaccine likely in May 2010.. Check out TheStreet for the latest stock market news and financial investment headlines.http://www.thestreet.com/_yahoo/story/10620223/1/dendreon-resubmits-provenge-to-fda-biobuzz.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NADendreon CorporationMon, 02 Nov 2009 13:56:04 GMThttp://www.prnewswire.com/news-releases/dendreon-announces-webcast-presentations-at-upcoming-investor-conferences-67183557.htmlSEATTLE, Oct. 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following upcoming investor conferences.http://www.prnewswire.com/news-releases/dendreon-announces-webcast-presentations-at-upcoming-investor-conferences-67183557.htmlDendreon CorporationThu, 29 Oct 2009 11:30:00 GMThttp://www.newratings.com/en/main/company_headline.m?id=1980710NEW YORK, October 23 (newratings.com) - Analysts at Canaccord Adams initiate coverage of Dendreon (ticker: DNDN) with a "buy" rating. The target price is set to $43. [more]http://www.newratings.com/en/main/company_headline.m?id=1980710Dendreon CorporationTue, 27 Oct 2009 11:11:08 GMThttp://seekingalpha.com/article/166090-dendreon-new-board-members-appointed-things-have-never-looked-brighter?source=feedVFC submits: Shares of Dendreon (DNDN) traded higher by nearly eight percent during early trading on Monday after it became apparent thathttp://seekingalpha.com/article/166090-dendreon-new-board-members-appointed-things-have-never-looked-brighter?source=feedDendreon CorporationMon, 12 Oct 2009 21:41:45 GMThttp://www.forbes.com/2009/09/25/cancer-provenge-dendreon-business-healthcare-dendreon.html?partner=yahootixDendreon, the Seattle drugmaker, held a meeting for Wall Street analysts in New York yesterday, highlighting its progress in manufacturing the prostate cancer treatment Provenge. Investors didn't like what they heard.http://www.forbes.com/2009/09/25/cancer-provenge-dendreon-business-healthcare-dendreon.html?partner=yahootixDendreon CorporationFri, 25 Sep 2009 17:50:00 GMThttp://www.cnbc.com//id/330211032,226 percent. That is the astronomical increase in shares of baby biopharma Vanda so far this year. And it's the prime historical example of "Biotech Takeouts and Breakouts" Bernstein's Geoffrey Porges uses in a sequel research note to clients he put out today.http://www.cnbc.com//id/33021103Dendreon CorporationFri, 25 Sep 2009 00:00:00 GMThttp://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/09-04-2009/0005088726&EDATE=SEATTLE, Sept. 4 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following four upcoming investor conferences.http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/09-04-2009/0005088726&EDATE=Dendreon CorporationFri, 04 Sep 2009 21:43:00 GMThttp://www.fool.com/investing/general/2009/09/03/drink-in-these-5-top-stocks.aspxWhether it's the corporate lunchroom, your cubicle, or the local watering hole after work, there are regular places we gather to discuss news, sports or -- if you're like us -- stocks.http://www.fool.com/investing/general/2009/09/03/drink-in-these-5-top-stocks.aspxDendreon CorporationThu, 03 Sep 2009 18:33:30 GMThttp://www.bizjournals.com/seattle/stories/2009/08/10/daily13.html?ana=from_rssDendreon Corp. reported a second-quarter loss of $126.7 million, or a loss of $1.20 per share, which compares with a loss of $16.5 million, or a loss of 18 cents per share a year earlier. In the latest quarter, the Seattle biotech (NASDAQ: DNDN) reported a $105.http://www.bizjournals.com/seattle/stories/2009/08/10/daily13.html?ana=from_rssDendreon CorporationTue, 11 Aug 2009 15:32:41 GMThttp://www.reuters.com/article/privateEquity/idUSN2322447220090723?feedType=RSS&feedName=privateEquity* Dendreon searches for international licensing partner * Shares rise 7.7 percent PHILADELPHIA, July 23 (Reuters) - Dendreon Corp has hired JPMorgan Chase & Co as ahttp://www.reuters.com/article/privateEquity/idUSN2322447220090723?feedType=RSS&feedName=privateEquityDendreon CorporationThu, 23 Jul 2009 15:02:22 GMThttp://www.rttnews.com/Content/QuickFacts.aspx?Node=B1&Id=941697%20&Category=Quick%20FactsRTTNews delivers all the important global financial news, Market analysis, Economics, stock alerts,forex and any news that may impact individual stocks,specific commodities, currencies and markets as a wholehttp://www.rttnews.com/Content/QuickFacts.aspx?Node=B1&Id=941697%20&Category=Quick%20FactsDendreon CorporationFri, 08 May 2009 10:40:32 GMThttp://www.bloomberg.com/apps/news?pid=20601087&sid=aKqaOqYYbgW4&refer=home[bn:WBTKR=DNDN:US] Dendreon Corp. []’s 69 percent plunge yesterday began with orders to sell hundreds of thousands of shares at whatever [bn:WBTKR=DNDN:US] price [] buyers would pay for them.http://www.bloomberg.com/apps/news?pid=20601087&sid=aKqaOqYYbgW4&refer=homeDendreon CorporationWed, 29 Apr 2009 21:29:16 GMThttp://www.businessweek.com/investing/insights/blog/archives/2009/04/dendreons_myste.html?campaign_id=rss_dailyBiotech stocks are supposed to be volatile, but yesterday’s move in Dendreon (DNDN) was a bit much. In a matter of minutes, the biotech stock fell 70%, from 25 to 7.50, before trading was halted at 11.81. The truly strange...http://www.businessweek.com/investing/insights/blog/archives/2009/04/dendreons_myste.html?campaign_id=rss_dailyDendreon CorporationWed, 29 Apr 2009 20:53:00 GMThttp://www.nature.com/news/2009/090429/full/news.2009.414.html?s=news_rssThe vaccine, called Provenge (sipuleucel-T), trains the immune system to recognize and fight off prostate cancer cells. According to results presented at the American Urological Association meeting in Chicago, the vaccine reduced the risk of death by 22.http://www.nature.com/news/2009/090429/full/news.2009.414.html?s=news_rssDendreon CorporationWed, 29 Apr 2009 20:44:10 GMThttp://www.guardian.co.uk/business/feedarticle/8481266NEW YORK, April 29 (Reuters) - With approval of its groundbreaking cancer vaccine now looking like a slam dunk, Dendreon Corp has become a hot property likely to draw intense interest from the big drugmakers and biotechnology companies.http://www.guardian.co.uk/business/feedarticle/8481266Dendreon CorporationWed, 29 Apr 2009 20:22:08 GMThttp://www.marketwatch.com/news/story/dendreon-shines-drug-stocks-climb/story.aspx?guid=%7B9F83A0E8-ADD1-49D9-9687-7185F7B0D284%7D&dist=msr_1Dendreon Corp. led drug stocks higher early Wednesday as shares of the biotech group rocketed on results from a positive study for its prostate cancer therapy Provenge.http://www.marketwatch.com/news/story/dendreon-shines-drug-stocks-climb/story.aspx?guid=%7B9F83A0E8-ADD1-49D9-9687-7185F7B0D284%7D&dist=msr_1Dendreon CorporationWed, 29 Apr 2009 19:01:57 GMT